Single User License
INR 169825
Site License
INR 339650
Corporate User License
INR 509475

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hepatitis C Global Clinical Trials Review, H2, 2016

Hepatitis C Global Clinical Trials Review, H2, 2016


  Request for Sample Report

Executive Summary

Hepatitis C Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Hepatitis C Global Clinical Trials Review, H2, 2016" provides an overview of Hepatitis C clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis C. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12

Top Five Countries Contributing to Clinical Trials in Central and South America 13

Clinical Trials by G7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials 14

Clinical Trials by Phase in G7 Countries 15

Clinical Trials in G7 Countries by Trial Status 16

Clinical Trials by E7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials 17

Clinical Trials by Phase in E7 Countries 18

Clinical Trials in E7 Countries by Trial Status 19

Clinical Trials by Phase 20

In Progress Trials by Phase 21

Clinical Trials by Trial Status 22

Clinical Trials by End Point Status 23

Subjects Recruited Over a Period of Time 24

Clinical Trials by Sponsor Type 25

Prominent Sponsors 26

Top Companies Participating in Hepatitis C Therapeutics Clinical Trials 27

Prominent Drugs 28

Latest Clinical Trials News on Hepatitis C 29

Aug 11, 2016: New Interim Phase IIa Data on Simeprevir in Combination with Other DAAs Will Be Presented at the Upcoming EASL AASLD Special Conference 29

Aug 08, 2016: Results from Merck's Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine 29

Jun 21, 2016: Trek Therapeutics Initiates Phase 2a Study of Faldaprevir and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b 30

Jun 21, 2016: Ascletis Publishes Interim Data of Phase II Study in Taiwan for its Interferon-free HCV Regimen 30

Jun 20, 2016: Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus 30

Jun 07, 2016: Regulus Reports Positive Top-line Data 32

Clinical Trial Profile Snapshots 33

Appendix 1744

Abbreviations 1744

Definitions 1744

Research Methodology 1745

Secondary Research 1745

About GlobalData 1746

Contact Us 1746

Disclaimer 1746

Source 1747

List of Figures

Hepatitis C Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9

Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10

Hepatitis C Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11

Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12

Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13

Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14

Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15

Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16

Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17

Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18

Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19

Hepatitis C Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20

Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21

Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22

Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23

Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24

Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25

Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26

Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

GlobalData Methodology 1745

List of Tables

Hepatitis C Therapeutics, Global, Clinical Trials by Region, 2016* 6

Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9

Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10

Hepatitis C Therapeutics Clinical Trials, North America, Top Countries, 2016* 11

Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12

Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13

Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14

Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15

Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16

Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17

Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18

Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19

Hepatitis C Therapeutics, Global, Clinical Trials by Phase, 2016* 20

Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21

Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22

Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23

Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24

Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25

Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26

Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Johnson & Johnson

AbbVie Inc

Bristol-Myers Squibb Company

Vertex Pharmaceuticals Incorporated

C. H. Boehringer Sohn AG & Co. KG

Novartis AG

GlaxoSmithKline Plc

Hepatitis C Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Hepatitis C, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com